CWM
RXRX icon

Cranbrook Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cranbrook Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35
Closed -$237 – 454
2024
Q4 		$237 Hold
35
– – ﹤0.01% 395
2024
Q3 		$231 Buy
+35
New +$251 ﹤0.01% 362

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Cranbrook Wealth Management's RXRX Position: Q1 2025 in Review

Cranbrook Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 35 shares — an estimated $237 sold.

Cranbrook Wealth Management first reported a position in RXRX in Q3 2024 and held it in 2 quarters. The position peaked at $237 in Q4 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Cranbrook Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cranbrook Wealth Management sold 35 Recursion Pharmaceuticals shares in Q1 2025, an estimated $237.
  • Cranbrook Wealth Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Cranbrook Wealth Management's Recursion Pharmaceuticals position peaked at $237 in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Cranbrook Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.